Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0035412 (
rhabdomyosarcoma
)
6,156
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Alveolar rhabdomyosarcoma (ARMS) is an aggressive childhood cancer of striated muscle characterized by the presence of the PAX3-FOXO1A or PAX7-FOXO1A chimeric oncogenic transcription factor. Identification of their targets is essential for understanding ARMS pathogenesis. To this aim, we analyzed transcriptomic data from
rhabdomyosarcoma
samples and found that
P-cadherin
expression is correlated with PAX3/7-FOXO1A presence. We then show that expression of a PAX3 dominant negative variant inhibits
P-cadherin
expression in ARMS cells. Using mouse models carrying modified Pax3 alleles, we demonstrate that
P-cadherin
is expressed in the dermomyotome and lies genetically downstream from the myogenic factor Pax3. Moreover, in vitro gel shift analysis and chromatin immunoprecipitation indicate that the
P-cadherin
gene is a direct transcriptional target for PAX3/7-FOXO1A. Finally,
P-cadherin
expression in normal myoblasts inhibits myogenesis and induces myoblast transformation, migration and invasion. Conversely,
P-cadherin
downregulation by small hairpin RNA decreases the transformation, migration and invasive potential of ARMS cells.
P-cadherin
also favors cadherin switching, which is a hallmark of metastatic progression, by controlling N- and M-cadherin expression and/or localization. Our findings demonstrate that
P-cadherin
is a direct PAX3-FOXO1A transcriptional target involved in ARMS aggressiveness. Therefore,
P-cadherin
emerges as a new and attractive target for therapeutic intervention in ARMS.
...
PMID:P-cadherin is a direct PAX3-FOXO1A target involved in alveolar rhabdomyosarcoma aggressiveness. 2271 Jul 18